Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Compliance Chief Stresses Priorities on PMD Law Amendment, Steady Implementation of Detailing Guidelines
August 8, 2019
- MHLW Begins Discussions on Clinical Use of Human-Embryo Gene Editing
August 5, 2019
- MHLW Pharma Bureau Chief Keen on Early Enactment of PMD Amendment Bill
August 5, 2019
- Tecentriq’s SCLC Use Gets MHLW Panel Nod for September Approval
August 5, 2019
- Cost-Effectiveness Challenge Remains in Adding Rotavirus Vaccine to Public Vaccination Programs: MHLW Panel
August 5, 2019
- Nobelpharma’s Tympanic Membrane Perforation Drug Clears MHLW Panel, September OK Likely
August 2, 2019
- MHLW Finalizing Timing to Announce Post-Oct. 1 NHI Prices, Bureau Chief Hints at August Possibility
August 2, 2019
- Japan OKs FY2020 Budget Guidelines, Sets 530 Billion Yen Request Ceiling for Social Security Cost Rise
August 1, 2019
- Indonesia to Shorten Review Period for Japan-Approved Drugs
July 29, 2019
- Chuikyo to Revisit Generic Price-Band Rule
July 26, 2019
- Apply Essential Drug Price Maintenance Rule Soon after Unprofitability Re-Pricing: FPMAJ
July 25, 2019
- Chuikyo Wraps Up 1st Round of Discussions on 2020 Medical Fee Revision
July 25, 2019
- Chuikyo Cautious about Considering Societal Values in New Drug Pricing
July 25, 2019
- Don’t Cause Confusion in Drug Distribution in Tax-Linked Drug Re-Pricing: JPWA
July 25, 2019
- Industry’s Plea to Scrap PMP Company Criteria Gets Cold Shoulder at Chuikyo
July 25, 2019
- Regenerative Medicine Forum Opposes Lower Premium Rates for Cell & Gene Therapies, Wins Chuikyo Support for New Pricing Scheme
July 24, 2019
- 3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
- MHLW Panel to Review Tecentriq’s SCLC Use and More for September OK
July 23, 2019
- Nobelpharma’s Tympanic Membrane Perforation Treatment Up for MHLW Panel Review on Aug. 1
July 23, 2019
- LDP’s Eto Secures Upper House Seat
July 22, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…